Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5606- NaHCO3,    Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer
- Trial, PC, NA
Dose↝, OS↑, eff↑,
5605- NaHCO3,    A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
- Trial, HCC, NA
eff↑, Dose↝, other↓, OS↑, toxicity↓, AntiCan↓,
5604- NaHCO3,    Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
- vitro+vivo, Melanoma, B16-BL6 - in-vitro, BC, 4T1
eff↑, eff↑, TumMeta↓, pH↑, CaMKII ↑, CREB↑, PGC-1α↑, AntiTum↑, Imm↑, CD8+↑, TAMS↑,
5603- NaHCO3,  immuno,    Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
- in-vitro, BC, MCF-7 - in-vitro, PC, MIA PaCa-2 - in-vitro, GBM, U87MG
eff↑, e-pH↑, PD-L1↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,
5601- NaHCO3,    Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents
- vitro+vivo, Var, NA
e-pH↑, ChemoSen↑,
5600- NaHCO3,    Acidosis and Cancer: from Mechanism to Neutralization
- Review, Var, NA
e-pH↑, TumCG↝, eff↑,
1311- NarG,  Rad,    Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis
- in-vitro, Lung, H23
tumCV↓, ROS↑, Casp3↑, p‑Akt↓, Akt↓, MMP2↓, P21↓,
1798- NarG,    Naringenin: A potential flavonoid phytochemical for cancer therapy
- Review, NA, NA
*Inflam↓, *antiOx↓, neuroP↑, hepatoP↑, AntiCan↑, Apoptosis↑, TumCCA↑, angioG↓, ROS↝, SOD↑, TGF-β↓, Treg lymp↓, IL1β↓, *BioAv↝, ChemoSen↑, cardioP↑,
1797- NarG,    Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway
- in-vitro, BC, MDA-MB-231
TumCG↓, β-catenin/ZEB1↓, AntiTum↑, Apoptosis↑, TumCCA↑, P21↑, survivin↓,
1808- NarG,    Intake of flavonoids and lung cancer
- Analysis, NA, NA
AntiCan↑, CYP1A1↓,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
1806- NarG,    Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications
- Review, NA, NA
Inflam↓, antiOx↓, AntiCan↑, BioAv↓, BioAv↓, BioAv↑, INF-γ↓, IL6↓, TNF-α↓, IL10↑, CRP↓,
1805- NarG,    Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
- in-vitro, Ovarian, A2780S - in-vivo, NA, NA
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
1804- NarG,    Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms
- Review, NA, NA
GutMicro↝, BioAv↝,
1803- NarG,    Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review
- Review, Var, NA
JAK↓, STAT↓, PI3K↓, Akt↓, mTOR↓, NF-kB↓, COX2↓, NOTCH↓, TumCCA↑,
1802- NarG,  ATV,    Bioenhancing effects of naringin on atorvastatin
- in-vivo, Nor, NA
BioEnh↑, LDL↓, P450↓, P-gp↓,
1801- NarG,    A Narrative Review on Naringin and Naringenin as a Possible Bioenhancer in Various Drug-Delivery Formulations
- Review, Var, NA
AntiCan↓, CYP19↓, PI3K↓, Akt↓, TumAuto↑, eff↑, BioEnh↑,
1800- NarG,    Naringenin
- Human, Nor, NA
CYP19↓,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
4223- NarG,    Effect of 2-Week Naringin Supplementation on Neurogenesis and BDNF Levels in Ischemia–Reperfusion Model of Rats
- in-vivo, Stroke, NA
*neuroG↑, *BDNF↑, *motorD↑,
4224- NarG,    The Effect of Naringin on Cognitive-Behavioral Functions, CREB/BDNF Signaling, Cholinergic Activity, and Neuronal Density in the Hippocampus of an MSG-Induced Obesity Rat Model
- in-vivo, Obesity, NA - NA, AD, NA
*memory↑, *Mood↑, *CREB↑, *BDNF↑, *AChE↓, *cognitive↑, *neuroP↑,
4225- NarG,    Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury
- in-vivo, NA, NA
*motorD↑, *BDNF↑, *VEGF↑, *Bax:Bcl2↓, *Casp3↓, *Apoptosis↓, *eff↑,
928- NarG,  PacT,    Bioenhancers from mother nature and their applicability in modern medicine
- Review, Nor, NA
*BioEnh↑,
981- NarG,  QC,    Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer
- in-vivo, NA, NA
TumVol↓, CYP19↓,
1015- NarG,    Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells
- in-vitro, Cerv, SiHa - in-vitro, Cerv, HeLa - in-vitro, Cerv, C33A
ER Stress↑, p‑eIF2α↑, CHOP↑, PARP1↑, Casp3↑, β-catenin/ZEB1↓, GSK‐3β↓, p‑β-catenin/ZEB1↓, p‑GSK‐3β↓, TumCCA↑, P21↑, p27↑,
1129- NarG,    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity
- in-vitro, Pca, PC3
E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,
3759- NarG,  RT,  CGA,  RosA,    Polyphenols as acetylcholinesterase inhibitors: Structural specificity and impact on human disease
- Review, AD, NA
*AChE↓, *other↓, *other↓,
1268- NCL,  carbop,    Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer
- in-vitro, Ovarian, NA
Wnt/(β-catenin)↓, ALDH1A1↓, LRP6↓,
1269- NCL,    Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
- in-vitro, Pca, DU145
STAT3↓, TumCG↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cMyc↓, Bcl-xL↓,
1270- NCL,  Rad,    Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells
- in-vivo, Lung, NA
Hif1a↓, VEGF↓,
1271- NCL,    Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
- vitro+vivo, Ovarian, SKOV3
Wnt/(β-catenin)↓, mTOR↓, STAT3↓, NF-kB↓, NOTCH↓, TumCG↓, Apoptosis↑, MEK↓, ERK↓, mitResp↓, Glycolysis↓, ROS↑, JNK↑,
1267- NCL,    Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression
- in-vitro, HCC, NA
TumCP↓, cycD1/CCND1↓, MMP9↓, TumCMig↓,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, eff↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
5255- NCL,    Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial
- Trial, Nor, NA
BioAv↝, Dose↝, toxicity↓, BioAv↑, BioAv↝,
6493- Nimb,    Nimbolide, a Limonoid Triterpene, Inhibits Growth of Human Colorectal Cancer Xenografts by Suppressing the Proinflammatory Microenvironment
- in-vivo, CRC, HCT116 - vitro+vivo, CRC, HT29
TumCP↓, Apoptosis↑, NF-kB↓, IKKα↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, ICAM-1↓, VEGF↓, angioG↓, TumCG↓,
6494- Nimb,    Microwave-Assisted Improved Extraction and Purification of Anticancer Nimbolide from Azadirachta indica (Neem) Leaves
- Study, Nor, NA
other↝,
6491- Nimb,    Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells
- Review, PC, NA
eff↑, uPA↓, uPAR↓, p‑EGFR↓, VEGFR1↓, NF-kB↓, IKKα↓, MMP2↓, MMP9↓, TIMP2↑, TumCP↓, IGFR↓, Akt↓, ERK↓, TumCCA↓, BAX↑, BAD↑, FasL⇅, Cyt‑c↑, EPR↑,
6492- Nimb,    Review on Molecular and Chemopreventive Potential of Nimbolide in Cancer
- Review, NA, NA
Apoptosis↑, TumCCA↑, TumCP↓, TumCI↓, angioG↓, TumMeta↓, PTEN↑, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, IKKα↓, CXCR2↓, CXCR4↓, Bcl-2↓, COX2↓, MMP9↓, VEGF↓, TIMP2↑, chemoPv↑, ROS↑, DR4↑, P53↑, BAX↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Mcl-1↓, XIAP↓, survivin↓, FasL↑, FADD↑, EGFR↓, MMPs↓,
6490- Nimb,    Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer
- in-vitro, Oral, SCC4
PI3K↓, Akt↓, GSK‐3β↑, MMP↓, Apoptosis↑, Bax:Bcl2↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp9↑, TumAuto↑, Beclin-1↓, p62↑, PI3K↓, chemoPv↑,
6489- Nimb,    Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model
- in-vivo, Pca, DU145 - in-vivo, Pca, LNCaP
tumCV↓, Apoptosis↑, TumCI↓, TumCMig↓, STAT3↓, ROS↑, TumCG↓, TumMeta↓, TumCCA↑, DNAdam↑, Casp3↑, Casp7↑, cl‑PARP↑, p‑STAT3↓, IL6↓, GSR↓,
6488- Nimb,    Harnessing the Anti-Cancer Natural Product Nimbolide for Targeted Protein Degradation
- in-vitro, BC, NA
TumCP↓, AntiTum↑, TumMeta↓, selectivity↑,
6485- Nimb,    Limonoids from neem (Azadirachta indica A. Juss.) are potential anticancer drug candidates
TumCG↓, TumCP↓, Apoptosis↑, Inflam↓, angioG↓, DrugR↓,
6486- Nimb,    Nimbolide: promising agent for prevention and treatment of chronic diseases
- Review, Var, NA - Review, AD, NA
*other↝, *Inflam↓, AntiCan↑, *Bacteria↓, *AntiViral↑, *neuroP↑, *hepatoP↑, *ROS?, *NRF2↑, *HO-1↑, *TLR4↓, *NF-kB↓, *AChE↓, *Aβ↓, *GSK‐3β↓, *LDL↓, *DNAdam↓, *lipid-P↓, *antiOx↑, *SOD1↑, *GSH↑, *IL6↓, *IL1β↓, *STAT3↓, *GPx↑, *Catalase↑, *MDA↓, *AntiDiabetic↑, *HDL↓, *MCP1↓, *VEGF↓, *MMP9↓, *GutMicro↑, TumCP↓, TumCCA↑, TumCMig↓, NF-kB↓, ROS↑, PI3K↓, Akt↓, mTOR↓, ERK↓, EMT↓, TumMeta↓, ChemoSen↑, eff↑, selectivity↑, CDK4↓, CDK6↓, Wnt↓, β-catenin/ZEB1↓, STAT3↓, MMP2↓, Sp1/3/4↓, AP-1↓, P21↑, *AntiArt↑, *IL23↓, *IL17↓, *IFN-γ↓, *HSP70/HSPA5↓,
6487- Nimb,    Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development
- Review, Var, NA
TumCP↓, Apoptosis↓, TumMeta↑, angioG↓, *antiOx↑, *eff↑, Apoptosis↑, MOMP↑, CDK1↓, TumCCA↑, MAPK↓, JAK2↓, STAT3↓, PI3K↓, Akt↓, TumCP↓, *NRF2↑, NF-kB↓, GSK‐3β↑, Wnt↓, β-catenin/ZEB1↓, chemoPv↑, Bcl-xL↓, Bcl-2↓, survivin↓, Cyt‑c↑, BAX↑, BID↑, cl‑Casp↑, P53↑, DR5↑, DR4↑, ROS↑, lipid-P↑, MDA↑, MMP2↓, MMP9↓, uPA↓, ICAM-1↓, CXCR4↓, CXCR2↓, angioG↓, BBB↑,
946- Nimb,    Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis
- in-vivo, NA, NA
Apoptosis↑, Bcl-2↓, P53↑, cl‑Casp3↑, Cyt‑c↑, ROS↑, SOD↓, Catalase↓, Glycolysis↓, GLUT3↓, LDHA↓, MCT1↓, NHE1↓, ATPase↓, CAIX↓,
4973- Nimb,    Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells
- in-vitro, NSCLC, A549
tumCV↓, ROS↑, ER Stress↑, DNAdam↑, Apoptosis↑, eff↓,
4970- Nimb,    Insights into Nimbolide molecular crosstalk and its anticancer properties
- Review, Var, NA
chemoPv↑, Apoptosis↑, TumCP↓, TumCD↑, TumMeta↓, angioG↓,
4971- Nimb,    Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal
- Review, Var, NA
TumCP↓, Apoptosis↓, TumCI↓, angioG↓, TumMeta↓, Inflam↓,

Showing Research Papers: 4601 to 4650 of 6648
Prev Page 93 of 133 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6648

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↓, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   GSH↓, 1,   GSR↓, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↑, 1,   ROS↑, 14,   ROS↝, 1,   SOD↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

EGF↓, 1,   ETC↑, 1,   MEK↓, 1,   mitResp↓, 1,   MMP↓, 1,   PGC-1α↑, 1,   e-Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   CAIX↓, 1,   cMyc↓, 3,   CREB↑, 1,   GLO-I↓, 1,   Glycolysis↓, 2,   LDHA↓, 1,   LDL↓, 1,   NADH:NAD↓, 1,   TCA↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 8,   p‑Akt↓, 2,   Apoptosis↓, 2,   Apoptosis↑, 14,   BAD↑, 1,   Bak↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   Bcl-xL↓, 3,   BID↑, 1,   Casp↑, 1,   cl‑Casp↑, 1,   Casp3↑, 5,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 4,   DR4↑, 2,   DR5↑, 2,   FADD↑, 1,   FasL↑, 1,   FasL⇅, 1,   JNK↑, 1,   MAPK↓, 2,   MAPK↑, 1,   Mcl-1↓, 3,   MCT1↓, 1,   MOMP↑, 1,   Myc↓, 1,   p27↑, 1,   p38↓, 1,   survivin↓, 5,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↑, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   other↓, 1,   other↝, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 2,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 5,   cl‑PARP↑, 2,   PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 4,   E2Fs↓, 2,   P21↓, 1,   P21↑, 3,   TumCCA↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   cFos↓, 1,   CSCs↓, 1,   Diff↑, 1,   EMT↓, 4,   ERK↓, 4,   GSK‐3β↓, 1,   GSK‐3β↑, 2,   p‑GSK‐3β↓, 1,   IGFR↓, 1,   LRP6↓, 2,   mTOR↓, 5,   p‑mTOR↓, 1,   mTORC1↓, 1,   NOTCH↓, 4,   PI3K↓, 8,   PTEN↑, 1,   RAS↓, 2,   STAT↓, 1,   STAT3↓, 8,   p‑STAT3↓, 1,   TumCG↓, 9,   TumCG↝, 1,   Wnt↓, 6,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

AntiAg↑, 1,   AP-1↓, 1,   ATPase↓, 1,   E-cadherin↓, 1,   KRAS↓, 1,   MMP2↓, 6,   MMP9↓, 7,   MMPs↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TIMP1↑, 1,   TIMP2↑, 3,   Treg lymp↓, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 14,   TumMeta↓, 7,   TumMeta↑, 1,   Twist↓, 1,   uPA↓, 3,   uPAR↓, 1,   VCAM-1↓, 1,   VEGFR1↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 7,   β-catenin/ZEB1↑, 1,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 9,   EGFR↓, 3,   p‑EGFR↓, 1,   EPR↑, 1,   HIF-1↓, 1,   Hif1a↓, 1,   TAMS↑, 1,   VEGF↓, 5,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT3↓, 1,   NHE1↓, 1,   P-gp↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CRP↓, 1,   CXCR2↓, 2,   CXCR4↓, 3,   ICAM-1↓, 2,   IFN-γ↑, 1,   IKKα↓, 3,   IL10↑, 1,   IL12↑, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 3,   Imm↑, 1,   INF-γ↓, 1,   Inflam↓, 3,   JAK↓, 1,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 9,   PD-1↓, 1,   PD-L1↓, 3,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

pH↓, 1,   pH↑, 1,   e-pH↑, 4,  

Protein Aggregation ⓘ

PP2A↑, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,   CYP19↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 5,   BioAv↝, 5,   BioEnh↑, 2,   ChemoSen↑, 6,   Dose↑, 1,   Dose↝, 5,   Dose∅, 1,   DrugR↓, 1,   eff↓, 1,   eff↑, 13,   Half-Life↓, 1,   Half-Life∅, 1,   P450↓, 1,   RadioS↑, 2,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

CRP↓, 1,   EGFR↓, 3,   p‑EGFR↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   IL6↓, 3,   KRAS↓, 1,   Myc↓, 1,   PD-L1↓, 3,  

Functional Outcomes ⓘ

AntiCan↓, 2,   AntiCan↑, 4,   AntiTum↑, 4,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 4,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 4,   toxicity↓, 4,   toxicity∅, 1,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 224

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   HDL↓, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS?, 1,   SOD1↑, 1,  

Core Metabolism/Glycolysis ⓘ

CREB↑, 1,   LDL↓, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Bax:Bcl2↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 2,   other↝, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   neuroG↑, 1,   STAT3↓, 1,  

Migration ⓘ

MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL23↓, 1,   IL6↓, 1,   Inflam↓, 2,   MCP1↓, 1,   NF-kB↓, 1,   TLR4↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 3,   BDNF↑, 3,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   BioEnh↑, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   Mood↑, 1,   motorD↑, 2,   neuroP↑, 2,  

Infection & Microbiome ⓘ

AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 54

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page